Navigation Links
Data on Higher Dose of Copaxone and Data Showing Copaxone is Most,Cost Effective

results of this study, a large-scale Phase III study designed to confirm the higher efficacy of COPAXONE with the increased dose has been initiated. The study, entitled FORTE (FORTy mg Efficacy of glatiramer acetate), was launched July, 2006, in 137 centers across North America, Europe, Argentina and Israel. Recruitment of approximately 1,000 patients is expected to be completed in May 2007. These dossiers, including these data, are expected to be submitted to the U.S. Food and Drug Administration in 2008.


Phase II Study Design and Results


The study was a randomized, double-blind, parallel-group study conducted at 18 centers in the U.S. in 90 patients with RRMS. The study evaluated the effect of 40 mg of COPAXONE (glatiramer acetate injection) given daily versus 20 mg of COPAXONE on disease activity as measured by MRI and clinical relapses, as well as the safety and tolerability of the 40 mg dose over a period of 9 months. Patients that qualified for this study had clinically-definite MS, had experienced a relapse in the previous year, had at least one Gd-enhancing lesion at screening visit, and had a Kurtzke Expanded Disability Status Scale (EDSS) score of 0-5. Patients were randomized in equal numbers to receive either 40 mg or 20 mg of COPAXONE . All patients underwent an MRI at baseline, and then at months 3, 7, 8 and 9. Neurological examinations were performed at screening, baseline, and again at months 3, 6 and 9, and suspected on-trial relapses were confirmed at an unscheduled visit within 7 days.


COPAXONE 40 mg showed a 38 percent greater reduction of inflammatory disease activity as measured by mean cumulative number of Gd-enhancing T1 MRI lesions versus COPAXONE 20 mg (p=0.0898). The benefit of the 40 mg dose was observed in as soon as 3 months (p=0.005) through MRI measurement. When compared to baseline numbers, the risk of having MRI activity (Gd-enhancement) in the 40 mg group at months 7, 8 and 9 was redu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-Remitting Multiple Sclerosis (RRMS)
2. New Clinical Study Results Indicate Higher Early Virologic Response with Celgosivir Combination Therapy in HCV Non-Responders
3. Diabetes Linked to Higher Parkinsons Risk
4. Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
5. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
6. Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis
7. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
8. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
9. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
Post Your Comments:
(Date:7/30/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the lifesciences ... him on Edwards, board as we pursue our focused innovation ... CEO.  "Bob has provided a valuable perspective to our board, ...
(Date:7/30/2015)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year. Reported sales decreased 4% as currency reduced sales ... earnings per diluted share as reported (EPS) were $2.73, ... was $2.80 , an increase of 9% over ...
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... 4, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... in Phoenix, Arizona on Thursday, November 11, 2010 at 5:30 ... Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will ... webcast live through the "Investors" section of Amylin,s corporate website ...
... N.C., Nov. 4, 2010 Gentris Corporation ( ... pharmacogenomics, announced today that Howard McLeod, Pharm.D., from ... (UNC) has become the Company,s first Chief Scientific ... pharmacogenomics and personalized medicine, is the Fred N. ...
Cached Medicine Technology:Gentris Corporation Names New Chief Scientific Advisor 2Gentris Corporation Names New Chief Scientific Advisor 3
(Date:7/31/2015)... , ... July 31, 2015 , ... “ Crack’em ” ... latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert and ... helps chefs make less mess while cooking. , Cooking can be a very messy ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Super-Sod wants ... with a Super-Sod Pro Page as the perfect fit for such a ... pictures and articles. The social website is a dynamic site that spreads home and ...
(Date:7/31/2015)... , ... July 31, 2015 , ... In the most ... U.S. District Court in the Northern District of Illinois, Androgel testosterone attorneys report that ... 20, a docket entry was made recording the minutes of the status conference, which ...
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional Products ... of nutritional and wellness products, announced the addition of Vincent Aquilino to its ... active isolated stretching and the prevention and rehabilitation of injuries, has spent the ...
(Date:7/31/2015)... ... , ... Easter Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will be held Saturday, ... AM. The duathlon is a 2 mile run, 13 mile bike ride, and a 3 ... mile bike, and a 3 mile run. Heels & Wheels is sponsored by Mayo ...
Breaking Medicine News(10 mins):Health News:Make Less Mess while Cooking with Crack’em 2Health News:Super-Sod Created a Landscape Profile on Houzz.com for Home Garden Design 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2
... , MONDAY, Dec. 5 (HealthDay News) -- When people with ... a third worrisome condition -- dementia -- goes up ... 2 diabetes are twice as likely to develop dementia three ... nondepressed people with diabetes, researchers found. "We,ve known for ...
... Calif. -- Aspirin taken within five days of cardiac ... risk of major postoperative complications, including renal failure, a ... (30-day mortality), according to a study by researchers at ... to appear in the journal Annals of Surgery ...
... been launched to help raise awareness of work being done ... childhood obesity and to seek the views of parents and ... of childhood overweight and obesity, led by a team of ... One-quarter of babies gain weight more rapidly than they should ...
... HealthDay Reporter , MONDAY, Dec. 5 (HealthDay News) -- ... using a preventive medication, according to new research. That ... the late 1980s. Preventive asthma medications help control ... the U.S. National Asthma Education and Prevention Program recommend their ...
... available in German . , The extent ... depends on motivation and will power or the physical condition ... latter particularly leads to noticeable and measurable performance impairments. For ... confined to changes in the muscle itself. Now, a joint ...
... 4 (HealthDay News) -- Variations in genes involved in ... disorder (ADHD), according to a new study. The ... may offer a new treatment option for ADHD patients ... researchers said. In the study, researchers conducted whole-genome ...
Cached Medicine News:Health News:Risk for Dementia Rises When Diabetes, Depression Meet: Study 2Health News:Risk for Dementia Rises When Diabetes, Depression Meet: Study 3Health News:Preoperative aspirin therapy can benefit cardiac surgery patients 2Health News:Parents' views sought on childhood obesity risk 2Health News:More Children Using Preventive Asthma Drugs: Study 2Health News:More Children Using Preventive Asthma Drugs: Study 3Health News:How muscle fatigue originates in the head 2Health News:More Evidence Links Specific Genes to ADHD 2
... enhances productivity in the laboratory with its ... methods clotting, chromogenic and immunological ... test results every time. With user ... random access, the CA-1500 will provide you ...
... Premier is our top-of-the-line device. ... attributes of the Qwik-Let® Elite, ... Lan-X feature. The Lan-X technology ... protection in the removal and ...
... the pain and hassle of testing. Unlike ... device is the only one with a ... testing, with less hassle and improved safety. ... and no side-to-side motion for less skin ...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
Medicine Products: